Skip subpage navigation
February 2016
- Clinical/Cost Presentation Meeting Window: November - December 2015
| Class Review |
Designated Newly Approved Drugs |
FDA Innovator Drugs |
- Oral Contraceptives
- Antifungal Agents - Topical Laquers
- Opthalmic Anti-Inflammatory/ Immunomodulatory Agents - Ophthalmic Immunomodulatory Agents
|
Tivorbex, Pazeo, Afrezza, Striverdi Respimat
Rexulti, Entresto -Solicitation cancelled
|
Adynovate, Alecensa, Coagadex, Cotellic, Durlaza, Dyanavel XR, Genvoya, Narcan nasal, Ninlaro, Seebri Neohaler, Strensiq, Tagrisso, Tresiba, Uptravi, Utibron Neohaler, Varubi, Veltassa, Vivlodex
|
May 11-12, 2016
- Clinical/Cost Presentation Meeting Window: March 2016
| Class Review |
Designated Newly Approved Drugs |
FDA Innovator Drugs |
- Oral Contraceptives - Emergency Contraceptives
- Anticonvulsants
- Antipsychotic Agents - Atypical
|
Entresto, Viberzi
Zecuity - Solicitation Cancelled
|
Adzenys XR-ODT, Belbuca, Enstilar, Idelvion, Kovaltry, Odefsey, Quillichew ER, Taltz, Vraylar, Xeljanx XR, Xuriden, Zepatier
|
August 10-11, 2016
- Clinical/Cost Presentation Meeting Window: May 2016
| Class Review |
Designated Newly Approved Drugs |
FDA Innovator Drugs |
- Acne Agents - Topical and Roseacea Agents
- Migraine Agents - Triptans
- Alcohol Deterrents - Narcotic Antagonists
|
N/A |
Afstyla, Briviact, Cabometyx, Aczone, Descovy, Epclusa, Ferriprox, Jentadueto XR, Nuplazid, Ocaliva, Orfadin, Sernivo, Onzetra Xsail, Zembrance SymTouch, Tolak, Ultravate, Venclexta, Xtampza ER |
November 16-17, 2016
- Clinical/Cost Presentation Meeting Window: August - September 2016
| Class Review |
Designated Newly Approved Drugs |
FDA Innovator Drugs |
- Anticoagulants - Oral Anticoagulants
- Antilipidemics-1 - PCSK9s
|
Spiriva Respimat
|
Bevespi Aeroshere, Byvalson, Emend, Gonitro, Invokamet XR, Otovel, Qbrelis, Relistor, Taytulla, Vonvendi, Xiidra, Yosprala, Zinbryta, Zurampic |
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: April 25, 2024